Although in a clinical setting islet transplantation is normally performed by percutaneous intrahepatic infusion, the kidney capsule has been the site of choice in nearly all the studies using mice. In the present study, we extensively characterized the mouse model of intraportally transplanted islets with the purpose to propose it as a model to study islet transplantation. C57BL/6 (n = 78) and BALB/C (n = 53) recipients were transplanted with 400 autologous islets alternatively through the portal vein (PV-Tx) or under the kidney capsule (KC-Tx). Glucose concentration during the first hour after syngeneic islet infusion was associated with subsequent long-term function confirming that early events have long-term effects on graft function. In both strains tested the probability to achieve islet function was significantly lower for PV-Tx than KC-Tx. Also in allogeneic models (C57BL/6 to BALB/C, n = 104; BALB/C to C57BL/6, n = 77) the probability to achieve primary function was significantly lower for PV-Tx than KC-Tx and the site of transplantation significantly affected the graft survival. Histological evaluation of livers showed the presence of features (embolism, thrombosis, focal areas of liver necrosis) that are absent in the kidney subcapsular site. Finally, significant differences in the outcome of PV-Tx were observed between the Th type 1 inflammatory-prone C57BL/6 mouse and the type 2 inflammatory-prone BALB/C mouse. Intraportal islet graft model has some features that are more similar to human clinical islet transplantation and should be used as a model to study not only engraftment but also mechanisms of immune suppression and immune tolerance.
INTRODUCTION
ing engraftment in the liver (5) has been suggested to be a prime factor necessitating the very large number of islets needed to achieve normoglycemia (2). Investiga-Rodent models have been widely used to study the causal mechanisms of failure of islet transplantation and tion of the mechanisms of islet cell loss during intahepatic islet transplantation and of ways to prevent their loss to test protocols aimed at preventing islet graft failure. In most rodent models, islets are transplanted under the would seem important (24, 27) . Yet, few studies in murine models address this be means of intrahepatic trans-kidney capsule, whereas islet transplantation in humans is performed by percutaneous intrahepatic infusion plantation. A systematic study of the intrahepatic islet transplant in the mouse model is also lacking. through the portal vein (25). Intrahepatic islet infusion in humans is associated with an immediate blood-medi-Here we describe allogenic and syngeneic intrahepatic islet transplantation models in two mouse strains, ated inflammatory reaction, thrombosis, and hepatic tissue ischemia (1,2,4-6, 13, 18, 22, 23, 28) . Kidney subcap-describe outcome in detail, and compare it with that of renal subcapsular islet transplantation. The findings sular transplantation is not intravascular and is devoid of these complications. Thus, although transplantation show marked differences in outcome between the models that appear to be largely attributable to engraftment. under the kidney capsule may be a useful model to study mechanisms of immune tolerance, it is likely to provide We propose, therefore, that the mouse model of intrahepatic islet transplantation via the portal vein be used as little clinically relevant information with respect to islet engraftment. Loss of as many as 50-75% of islets dur-a standard model for studies of islet engraftment.
MATERIALS AND METHODS
removed from the portal vein and then pressure was applied until all bleeding stopped. The peritoneal cavity Islet Transplantation was closed. For both kidney subcapsule and liver portal Islet Isolation and Culture. Pancreatic islets were vein transplants, 400 islets were injected. This number isolated from C57BL/6 or BALB/C mice (9 weeks old, was derived from preliminary experiments using in-20-22 g; Charles River, Calco, Italy) by a collagenase creasing islet numbers (100-500). In these experiments, digestion method. Briefly, 2 ml of cold Hank's buffer/ 300 islets were the minimal mass required for correction collagenase type V solution (1 mg/ml; Sigma, St. Louis, of hyperglycemia when injected through either portal MO, USA) was infused into the pancreatic duct in situ, vein or when placed under the kidney subcapsule, and the removed pancreas was digested at 37°C for 15 whereas 500 syngeneic islets caused a high rate of mormin. Islets were purified on a discontinuous Ficoll graditality in portal vein transplants. ent (Sigma). The islets (250 islet/ml) were cultured free-Evaluation of Graft Function floating (37°C, 5% CO 2 ) in RPMI-1640 medium (Bio-Whittaker, Walkersville, MD, USA) supplemented with Blood sugar levels were measured 15, 30, and 60 min L-glutamine (Sigma), penicillin and streptomycin (1000 after the end of surgical procedure, daily for the first U/ml and 10 mg/ml; Sigma), and 10% (v/v) fetal calf week and then every second day posttransplantation. serum (HyClone, Celbio, Logan, UT, USA) for [20] [21] [22] [23] [24] Surgical death was defined as death within the first 7 h before the transplant. Islet purity was >90%.
days after transplantation. In the allogenic model, primary nonfunction was defined as the inability to reach Recipient Mice. Male C57BL/6 or male BALB/C nonfasting blood glucose levels under 250 mg/dl for two mice (9 weeks old, 20-22 g; both from Charles River) consecutive measurement after islet transplantation, and were used as recipients. Mice were made diabetic (nonrejection was defined as two successive measurements fasting blood glucose levels between 400 and 600 mg/ >250 mg/dl in mice where primary function was dl) with intravenous STZ injection (175 to 200 mg/kg; achieved. In syngeneic models, transplants were classi-Sigma) 1-2 weeks prior to transplantation. Blood glufied as full function (nonfasting blood glucose concencose measurements were performed using a Glucometer tration <50% pretransplant concentration for at least 1 Elite (Bayer Canada, Toronto, Ontario, Canada). The anweek; FF), partial function (nonfasting blood glucose imals had free access to tap water and pelleted food concentration between 50% and 80% of pretransplant throughout the course of the study. The local animal ethconcentration for at least 1 week; PF), or no function ics committee approved all experiments.
(nonfasting blood glucose concentration >80% pretrans-Islet Transplantation Under the Kidney Capsule.
plant concentration for at least 1 week; NF). The recipient mice were anesthetized with isoflurane In some mice, an intravenous glucose tolerance test (Forane 1-2%; Abbott Laboratories, Toronto, Canada).
(IVGTT) was performed 2 and 6 weeks after transplan-Islets were transplanted as previously described (20) .
tation to demonstrate the function of the grafted islets. Briefly, after exposure of the left kidney, P-50 tubing IVGTT was initiated after a 16-h fast; mice in each excontaining the islets was inserted through a small inciperimental group were given glucose (0.5 g/kg) by tail sion into the lower pole of the kidney and pushed to vein injection. Blood samples were obtained at 0, 1, 5, the upper pole, whereupon the islets were gently pushed 10, 15, 20, 30, and 60 min after injection and were used beneath the kidney capsule, the cannula was removed, to determine glucose concentrations. From the IVGTT, and the incision was cauterized.
the glucose tolerance was quantified from the glucose elimination constant (K G ; expressed as percent elimi-Islet Transplantation Via the Portal Vein Route. Islets were transplanted via the portal vein. The recipient nation of glucose per minute) as the reduction in circulating glucose between 1 and 60 min (K G 60) after mice were anesthetized with isoflurane and then prepared for abdominal surgery. A 2-cm midline incision intravenous administration following logarithmic transformation of the individual plasma glucose values (19,26). was made slightly below xyphoid. The intestines were gently reflected leftward from the peritoneal cavity onto Evaluation of Graft Morphology dampened gauze and the portal vein was exposed. The islets were suspended in 0.3-0.5 ml RPMI-1640 me-For morphological investigations the recipients were killed at different times after transplantation: the liver dium aspirated from a 1.5-ml plastic tube into a heparinized plastic 1-ml syringe with a 29-gauge 12.5-mm nee-was removed and fixed in 10% buffered formalin and processed for histology. Histologic sections were stained dle. The needle was then inserted into the exposed portal vein and the plunger was gently advanced to expel the with hematoxylin and eosin (H&E) or for insulin with the use of an anti-insulin guinea pig primary polyclonal islets into the portal vein. A small piece of gelfoam was placed directly over the hole as the needle was being antibody (Dako, Carpinteria, CA, USA). The peroxidase-antiperoxidase immunohistochemistry method (LSAB-2 C57BL/6 mouse (C57BL/6-Tx; n = 44) and the Th type 2 inflammatory-prone BALB/C mouse (BALB/C-Tx; Kit; Dako) or AffiniPure anti-guinea pig tetramethylrhodamine-5 (and 6)-isothiocyanate (TRITC) secondary ann = 24) (14, 15) . Transplant function was monitored by measuring nonfasting glycemia 15, 30, and 60 min after tibodies (Jackson ImmunoResearch Laboratories) were used for detection.
the end of surgical procedure, daily for the first week and then every second day posttransplantation. In some Statistical Analysis animals an IVGTT 2 and 6 weeks after transplantation was also performed. A comparative analysis for the en-Significance of difference between groups was tested using the Mann-Whitney U-test, Kruskal Wallis test, graftment of the same number of islet under the kidney capsule (KC-Tx; n = 63) was performed. Pearson chi-square tests, and one-way ANOVA test. Survival differences were tested using the log rank sta-In both strains the probability to achieve islet full function (FF) was significantly lower for PV-Tx than tistic. For all analyses, a two-tailed value of p < 0.05 was considered significant. Statistical analyses were per-KC-Tx (Fig. 1) . The increased frequency of transplant failure in PV-Tx is due both to a higher frequency of formed using the Statistical Package for Social Science (SPSS 11.0; SPSS, Chicago, IL).
mouse death and to an increased frequency of partial function (PF) and no function (NF). In PV-Tx model islets displayed functional activity immediately after in-RESULTS fusion and glycemia decreased in the first hour after C57BL/6 or BALB/C Syngeneic Islet Transplantation transplantation. Glucose concentration during this time Via the Portal Vein: Models of Islet Engraftment was associated with subsequent classification of transplants as FF, PF, or NF (p = 0.006), suggesting that Sixty-eight STZ severely diabetic mice (mean nonfasting glycemia before transplantation: 539 ± 80 mg/dl) early events following intraportal injection have longterm effects on islet graft function both in BALB/C-Tx were transplanted with 400 sygeneic islets into the liver through the portal vein (PV-Tx). Two different mouse and C57BL/6-Tx ( Fig. 2A) . Glycemia continued to differ between FF, PF, and NF transplants ( Fig. 2B ). FF strains were tested: the Th type 1 inflammatory-prone transplants improved metabolic control and gradually 0.17) and to an increase frequency of NF (29% vs. 10%, p = 0.10). reached and maintained maximal function within 3-4 weeks and mice with FF transplants had long-term sur-Islet Transplantation Via the Portal Vein: vival. PF and NF transplants progressively lost function Characterization of Allogenenic Model (C57BL/6 and mice died as a result of uncontrolled diabetes. Gluto BALB/C and BALB/C to C57BL/6) cose tolerance (K G 60) 2 and 6 weeks after transplantation was consistent with the nonfasting glyaemia data STZ diabetic BALB/C or C57BL/6 recipients (nonfasting glycemia before transplantation: 436 ± 95 mg/dl) (Fig. 3A) . Liver histology performed 100 days posttransplant in surviving mice showed several islets present in were transplanted with 400 allogeneic C57BL/6 or BALB/C islets alternatively through the portal vein or liver parenchyma close to blood vessels of portal space (Fig. 3B ). In the PV-Tx model islet engraftment differed under the kidney capsule (C57BL/6 to BALB/C: PV-Tx n = 47, KC-Tx n = 72; BALB/C to C57BL/6: PV-Tx between the C57BL/6 and the BALB/C strain. One hour after transplantation glucose concentrations were lower n = 12, KC-Tx n = 55). The probability to achieve primary function was sig-in BALB/C-Tx than in C57BL/6-Tx (p = 0.001) ( Fig.  2A) . During the subsequent 8 weeks of observation, FF nificantly lower for PV-Tx than KC-Tx in both strains (Fig. 4A ). Primary function of the islets (blood glucose or PF islet function was achieved in 18/24 (75%) of BALB/C-Tx and 21/44 (48%) of C57BL/6-Tx (p = concentration <250 mg/dl within 5 days after transplantation) was achieved in 24/47 (51.1%) of PV-Tx and 58/ 0.03) (Fig. 1) . Moreover, BALB/C-Tx generally showed a better K G 60 than C57BL/6-Tx at any time tested. The 72 (80.6%) of KC-Tx (p < 0.001) in C57BL/6 to BALB/ C transplantation, and in 6/12 (50%) of PV-Tx and 54/ increased frequency of transplant failure in C57BL/6-Tx appeared due both to a higher frequency of mouse death 55 (98.8%) of KC-Tx (p < 0.001) in BALB/C to C57BL/6 transplantation. The increased frequency of in the first 7 days after transplant (32% vs. 17%, p = transplantation failure was due to a higher number of cipient pretransplant glycemia was performed. The recipient severity of diabetes was added because it is a deaths attributed to the surgical procedure (15/59 vs. 3/ 127, respectively, for PV-Tx and KC-Tx; p = 0.001) and significant independent factor for graft survival in this model, as we have recently demonstrated (17) . The anal-higher number of primary nonfunction in the surviving mice (14/59 vs. 12/127, respectively, for PV-Tx and ysis confirmed as significant independent risk factors for the loss of graft survival: a) the portal vein route (odds KC-Tx; p = 0.001).
The site of transplantation affected the graft survival ratio: 3.6, 95% interval of confidence: 2.2-5.8, p < 0.0001), b) the C57BL/6 strain as recipient (odds ratio: in mice that achieved function posttransplant. In C57BL/ 6 to BALB/C transplantation, the median survival time 1.7, 95% interval of confidence: 1.2-2.5, p = 0.006), and c) the pretransplant glycemia (odds ratio: 1.003, of the islets was 7 ± 0.22 days (n = 24) and 21 ± 2.2 days (n = 58), respectively, in PV-Tx and KC-Tx (p < 95% interval of confidence: 1.001-1.005, p = 0.001).
A histological time course study of the liver after al-0.0001) (Fig. 4B) . In BALB/C to C57BL/6 transplantation, the median survival time of the islets was 4 ± 0.2 logeneic islet transplantation was performed (Fig. 4C ). Immediately after infusion, islets localized in the blood days (n = 7) and 19 ± 1.2 days (n = 54), respectively, in PV-Tx and KC-Tx (p < 0.0001) (Fig. 4B) . Moreover, vessels of portal spaces, they appeared to be healthy, they stained strongly for insulin, and they consistently both in PV-Tx and in KC-Tx the graft survival was lower in BALB/C to C57BL/6 combination than in the induced the formation of thrombi ( Fig. 5A-C) . After 24 h, pathologic changes of the tissue surrounding the islets reverse one. To confirm the data, a Multivariate Cox Regression Analysis including site, mouse strain, and re-were evident. The islets appeared to be trapped in the blood vessel and to have disrupted the downstream relatively spared (Fig. 5G ). Subsequently, infiltrates became massive, dense, and multifocal (Fig. 5F ). Six to 9 blood supply. The hepatocytes in the ischemic region had abnormal cell shapes and texture, and necrotic days after Tx, mononuclear leucocyte infiltrates colonized islets (Fig. 5G-H) , starting as peri-islet and be-wedge-shaped regions appeared (Fig. 5D-F) . After 24-72 h, starting from portal space, leucocyte infiltrates coming intraslet, with progressive endocrine tissue destruction and loss of the insulin staining. colonized the necrotic hepatic regions while islets were A comparative histological time course study of the any evidence of intraislet localization until the last day of observation (day +14). transplant under the kidney capsule was performed (Fig.  4D ). Immediately after transplantation, islets localized DISCUSSION under the kidney capsule, they appeared to be healthy, and they stained strongly for insulin ( Fig. 6A, B) . Be-Intraportal islet transplant is the preferred site for clinical islet transplantation. Despite this, the mouse sides their main endocrine constituent, islet grafts also contained few contaminating exocrine cells. After 24 h, model of intraportally transplanted islets is poorly characterized (7,16) and rarely used with the exception of pathologic changes of the islets were evident: necrotic area appeared in the central region of the bigger islets very few studies evaluating peculiar aspects such as the immediate blood-mediated inflammatory reaction after while the smaller ones were relatively spared (Fig. 6C ). After 24-72 h connective tissue infiltrated interislet xenotransplantation (8, 12) or the role of hepatic tissue ischemia (9,28) in transplant outcome. In the present space and subsequently became massive, dense, multifocal, and surrounded all the islets (Fig. 6C, D) . Four to 5 study, we extensively characterized this model with the purpose to propose it as a mouse model to study islet days after Tx, few mononuclear leukocytes surrounded the transplant without any significant increase until the transplantation and in particular engraftment during transplantation. last day of observation (day +14). Seven to 10 days after Tx few lymphocytes infiltrated peri-islet space without Numerous differences were observed between the liver portal vein and kidney subcalpsular islet trans-portal vessels and the size of the islets is substantially smaller than in humans where the vessels are larger. In plants. Histological evaluation of livers following portal vein islet transplant showed the presence of embolism, fact, the average portal diameter in humans is significantly greater than in mice [about 1 cm against 0.84 ± thrombosis, and numerous focal areas of liver necrosis around the transplanted islets. Obviously these compo-0.23 mm (10)] The mean diameter of transplanted islets is 0.113 ± 59 mm (n = 56) and 0.15 ± 64 mm (n = 146), nents are absent in kidney subcapsular islet transplants. Ischemia and necrosis of the liver occured maximally at respectively, for mouse and human. This means a portal vein/islet ratio of 66.6 in human versus 7.4 in mouse day 1, were reduced by day 3, and were largely resolved by day 7 after transplantation. The interpretation of these transplant. As a result, liver damage in mice could be more pronounced following islet transplantation than in observations is that the islet transplants block the blood flow to the capillary bed, resulting in acute necrosis of humans because a larger portion of liver is excluded from portal blood flow. Is this a relevant limit of the the surrounding liver tissue, and our observations suggest that the ischemic liver recovers through active re-mouse intraportal model for human studies? Probably not. From what we know, no substantial dimension dif-generation.
In the mouse the ratio between the diameter of the ference in small liver vessel and capillary is present be-tween mouse and human, suggesting that portal size dif-long-term function of islet graft are significantly different between the liver portal vein and kidney subcapsular ference should not be relevant at the level of single islet microenvironment in terms of ischemia and reperfusion. islet transplants. Islet transplantation via the portal vein route has some features that are more similar to human Moreover, even if we do not have the possibility to comparatively evaluate in humans what happens from an clinical islet transplantation and should be used as a model to study not only engraftment but also mecha-histological point of view, substantial evidence of liver embolism, thrombosis, and damage has been documented, nisms of immune suppression and immune tolerance. with increased level of cross-linked fibrin degradation ACKNOWLEDGMENTS: This work was supported by Teleproducts and raised liver aspartate and alanine amino- 
